paths. One path was bas ed on the premise that speci® c injury from a compound can be more easily established by administration only during certain periods of gestation. The procedure was used for com pounds s uch as drugs , which are usually taken on a one-time or s hort-term basis. For example, after the thalidomide tragedy (des cribed by Schardein, 1993) , the U.S. Food and Drug Adminis tration (FDA) Bureau of Drugs issued guidelines to measure the effects of drugs during three periods of reproduction: (1) fertility, conception, and early stages of gestation, (2) intrauterine development during organogenesis, and (3) late fe tal de velopme nt, deliver y, lactation, and pos tna tal viability an d growth. These FDA guidelines are commonly referred to as Segment I, II, and III studies (U.S. FDA, Bureau of Drugs, 1966) .
The second path was devis ed for compounds likely to involve chronic expos ur e an d f or w hich t here m ay be a con ce ntration fa ctor w he n administered during several generations. For thes e compounds, s peci® c procedures were developed that measured the effects of a compound during several generations . In 1949, the ªProcedures for the Appraisal of the Toxicity of Chemicals in Foods º by the s taff of the FDA's Division of Pharmacology (Lehman et al., 1949) included an outline for a procedure to test the effect of a compound fed continuous ly through three generations. The intent was to test the pos sible cumulative effect on fertility or on s peci® c s ex organs that might result from expos ure to a compound administered from conception to weaning of young for three generations.
The basic guidelines for the protocol for the three-generation reproduction s tudy were described in 1959 as part of the appraisal of the safety of chemicals in foods, drugs, and cosmetics (U.S. FDA, Division of Pharmacology, 1959) . Because of the color of the cover, the document was commonly referred to as the ªGrey Book.º The document is considered a cornerstone for guidelines for current toxicity testing. In the document, guidelines were provided for measurement and analysis of the number of matings, number of pregnancies , and number of young in the litters at days 1, 5, and 21 of life for ® rst-, second-, and third-generation animals. When tes ts were conducted according to these guidelines, the accumulated effects of a test chemical could be evaluated.
In 1963, the President's Science Advisory Committee emphas ized the need to determine the safety of compounds by recommending measurement of the ªeffects on reproduction through at leas t two generations in at leas t tw o s pecies of wa rm-bloode d anim als . Obs ervations s hould include effects on fertility, size, and weight of litter, fetal mortality, tera togenicity, grow th, and developm ent of s ucklings and wea nlings .º Since this report, the FDA has required a multigeneration reproduction s tudy in the evaluation of food additives and food contaminants, including pes ticides that may remain as res idues on raw agricultural products.
Fitzhugh (1968) further elaborated the protocol for multigeneration studies in his review of reproduction tes ts . Many reproduction studies have been done since 1968, and Fitzhugh's procedure is accepted as a means of determining the poss ible hazards of chronic exposure from compounds on mothers and embryos. The multigeneration study is the testing method of choice when there is need for an overall view of reproductive function that cannot be achieved by speci® c, shorter tests. It is used when there is the possibility that s ex organs will be affected, for example, delayed formation and maturation of gonads and gametes, transport of gametes, fertilization, implantation, lactation quality and quantity, and altered genetic makeup.
In 1982, the Bureau of Foods issued detailed guidelines for testing the reproductive effects of compounds by teratology/developmental toxicity s tudies and by multigeneration toxicity studies . The guidelines were included in To x i (U.S. FDA, Bureau of Foods, 1982) . This book is commonly referred to as the ªRedbookº because of the color of its cover.
c o l o g i c a l P r i n c i p l e s f o r t h e S a f e t y A s s e s s m e n t o f D i r e c t F o o d A d d i t i v e s a n d C o l o r A d d i t i v e s U s e d i n F o o d
The need for adequate safety evaluation of food components and additives , pe s ticides , an d oth er en vir onm ental con tam in ants to w hich humans are chronically exposed has led regulatory agencies to propose several different guidelines for determining the toxicity of compounds to the r epr oductive proce s s and dur in g developm ent. S ince the early 1980s, several attempts have been made to eliminate differences among testing guidelines.
One of the ® rst attempts to harmonize testing guidelines was initiated by the Interagency Regulatory Liaison Group (IRLG, 1981) . This group comprised the following agencies: Cons umer Product Safety Comm is s ion, Environm en tal Pr otection Agency (EPA), Food a nd Dr ug Administration, Food Safety and Quality Service of the Department of Agriculture, and the Occupational Safety and Health Administration (OSHA) of the Department of Labor. This group recommended guidelines for teratogenicity studies.
At the present time, several regulatory agencies are reviewing and updating their guidelines. In the United States, these agencies include the Environmental Protection Agency and the Food and Drug Administration, where the guidelines for both reproduction and developmental toxicity are being reviewed, updated, and harmonized. The revisions of the FDA guidelines for developmental toxicity studies and multigeneration studies were bas ed on cons ultations with scientis ts w orldwide (Collins et al., 1991) and extens ive literature review. A draft of the revised guidelines was issued in 1993 (U.S. FDA, Center for Food Safety and Applied Nutrition, 1993). Since that time, additional changes have been made. The public drafts of the EPA guidelines for the prenatal developmental toxicity study and the study of reproduction and fertility effects were both iss ued in 1996 (U.S. EPA, 1996a (U.S. EPA, , 1996b . In Europe, the Organization for Economic Cooperation and Development (OECD) issued revised draft guidelines for both reproduction and developmental toxicity tes ts during 1996 (OECD, 1996a (OECD, , 1996b .
To prom ote the inter national harm onization of guidelines and to reduce differences in technical requirements for drug development, the FDA participated in the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Us e (ICH). The ICH is concerned with the harmonization of technical requirements for the regis tration of pharmaceutical products among three regions: the European Union, J apan, and the United States. Harmonization of reproductive toxicity testing was selected as a priority topic during the early s tages of the ICH initiative. After s everal drafts and comments, a ® nal draft of the guideline was endors ed by the participating agencies and issued as the ªInternational Conference on Harmonization; Guideline on Detection of Toxicity to Reproduction for Medicina l Products º ICH (U.S . FDA, 1994 ) . The guideline provides information on testing during de® ned stages of reproduction (developmental toxicity) and during long-term exposure (multigeneration studies ). The information is applicable to sponsors that submit applications to both the FDA Center for Drug Evaluation and Research (CDER) and the FDA Center for Biologics Evaluation and Research (CBER).
Since this pres entation is being made as part of a s ympos ium on updated procedures des cribed in the draft of the revision of the Redbook, ªRedbook II,º only the guidelines contained in it are described at length. The guidelines re¯ect today's current thinking. Because they are s till in draft f orm , s om e of the inform ation pres ented here m ay be changed before the ® nal text is published. The guidelines are described in three s ections : general recomm endations , developmental toxicity testing guidelines , and reproductive toxicity testing guidelines. After the description of the draft of FDA's guidelines , tabular summaries of current FDA, EPA, Organization for Economic Cooperation and Development (OECD), and ICH guidelines are provided to indicate where these documents are similar and where they diverge.
DRAFT FDA GUIDELINES

General Recommendations
The follow ing r ecom m endations are applica ble to all FDA toxicity s tudies :
1. Studies s hould be con ducted according to good laboratory practice regulations (GLPs ) (U.S. FDA, 1978 1996) . 3. Healthy animals that have not been subjected to previous experim ental procedures should be us ed. Generally, it is not pos sible to treat animals for infection during the cours e of a study without risk of an interaction between the drug used for treatment and the test s ubstance. 4. Test animals should be characterized by reference to their species, s train, sex, and weight or age. 5. Animals should be assigned to control and experimental groups in a s trati® ed random manner to minimize bias and ensure comparability acros s experimental and control groups for statistical purposes. Each animal must be assigned a unique number.
Developmental Toxicity Testing Guidelines
The purpos e of developmental toxicity studies is to evaluate the effects of the tes t compound on developing organisms . The developmental toxicity test may be used as part of a multigeneration study from either the ® rst or second generation or as a stand-alone study. If it is part of a multigeneration study, the fetuses have maximum expos ure to the test agent, from conception on. In a stand-alone study, treatment mus t begin early enough to include organogenesis for the s pecies us ed and should continue to the day before the end of gestation.
A dos e range-® nding study is recommended to determine the most appropriate doses, unles s suitable pharmacokinetic and metabolic data are available. The dose range-® nding study should preferably, but not necess arily, be done in pregnant animals. When pharmacokinetic and metabolic data and other information s ugges t the mos t appropriate species, that species s hould be used. This guideline may be used with substances given orally to the rat, mouse, hamster, or rabbit. Traditionally, the rat and the rabbit have been the most frequently used species. The animals are relatively easy to maintain in the laboratory, are small and therefore require less compound than would a larger animal, and have provided cons istent results that can be extrapolated to human effects. The strains selected should have high fecundity and should be sensitive to embryotoxins. All test and control animals should be young, mature animals of uniform age and size.
A suf® cient number of females should be us ed so that each tes t and control group consists of at least 20 pregnant animals at or near term. This is the minimal number of pregnant animals required for such studies. The objective is to ensure that enough litters are produced to permit effective evaluation of the test compound.
In-house mating of the animals is recommended. A suf® cient number of males should be mated to ensure a large gene pool. Each male may be mated either to one or two females . The following morning, each female should be examined for the presence of sperm in the vaginal lavage or the presence of a sperm plug. The presence of sperm or a sperm plug is considered day 0 of gestation in rodents. Day 0 of gestation in rabbits is the day insemination is performed or obs erved.
The tes t com pound s hould be adminis tered da ily thr oughout the treatment period. The minimum treatment period begins with implantation and ends with cesarean section. In rats , the approximate timing for this period includes days 6 through 20; in mice, days 6 through 18; in hamsters, days 4 through 15; and in rabbits, days 6 through 29. If the study is being conducted as part of a multigeneration study, the animals are exposed in utero until necropsy.
The test compound or vehicle should be administered via a route that most closely approximates the pattern of human expos ure. The tes t compound could be adminis tered via oral intubation (gavage), diet, or drinking water. The maximum volume of s olution that can be given by gavage in one dos e depends on the test animal's size and the vehicle; for rodents , this should not exceed 1 ml/100 g body weight for water solutions, and should not exceed 0.5 ml/100 g body weight for corn oil solutions. Each animal should be given a precis e dose. If the test compound is given by gavage, the volume should be adjusted either daily or every 3 days, based on the animal's body weight. In diet and drinking-water studies, the amount consumed depends on each animal.
At least three test groups and one concurrent control group should be used. The high dose should cause some toxicity to the dam and/or fetus, but not more than approximately 10% dam mortality. The high dose s hould not exceed 5% of the diet for nonnutritive additives. The low level s hould be set at a level that is expected to provide a minimal margin of safety and should not induce any observable effects attributable to the test compound. The intermediate dos e(s ) should be s pace d to allow an arithmetic or geometric progress ion between the low and high doses .
When the tes t s ubstance is adm inis tered in a vehicle, the vehicle without the test s ubstance should be administered to the control group at a volume equal to the maximum amount of vehicle given to any dosed group. If there are ins uf® cient data on the toxic properties of the vehicle us ed in adminis tering the tes t compound, a s ham con trol group should also be included. If no vehicle is used, then the controls should be sham treated. In all other res pects, the control animals should be han-dled and maintained in a manner identical to that us ed with the groups given the test compound.
Throughout the s tudy, each animal s hould be obs erved at least twice daily. The ® rst observation should include a thorough clinical examination. The second may involve observing the animals through the cages. Relevant behavioral changes and other signs of toxicity, morbidity, or mortality should be recorded. Any dam showing signs of imminent abortion or premature delivery should be necrops ied on the date such s igns are observed.
Dams should be weighed immediately before the ® rst dose of the test compound is adminis tered, weekly until necrops y, and at the time of necropsy. If the compound is given in the diet, weekly body weight is acceptable. If the compound is given by gavage, body weights should be measured daily or every 3 days. At a minimum, weekly measurements of feed consumption should be made. The feed cons umption of all animals should be measured on the same days, for example, for rats , days 0, 7, 14, and before cesarean section (on day 20 or 21). Water cons umption should be measured as appropriate.
The tes t s hould be terminated approximately 1 day before term (day 20 or 21 for rats, day 18 for mice, and day 29 for rabbits), when the dams should be necrops ied and s ubjected to gross pathologic examination. Immediately after the dams are killed, fetuses should be removed by hysterotomy (ces arean section). Evaluation of the females during cesarean s ections and subs equent fetal analyses s hould be conducted blind in order to minimize uncons cious bias.
The intact uterus should be removed and weighed in order to calculate the adjus ted body weight gain. The contents of the uterus should then be examined for embryonic or fetal deaths and for the number of live fetus es . The number of corpora lutea s hould be determined for all pregnant females. The uterus of each dam that does not appear to be pregnant should be stained in a solution of ammonium sul® de or other appropriate chemical to enhance the visibility of resorption sites.
After removal from the uterus, each fetus s hould be weighed, s exed, examined externally, and all deviations from normal should be noted. For rodents, approximately half of the fetuses should be pres erved in Bouin's s olution and sectioned by the Wilson serial section technique to evaluate visceral alterations. The remaining half of the fetus es should be ® xed and s tained with Alizarin red (optional stain Alcian blue for cartilage) to detect s keletal anomalies . Alternatively, rodent fetus es may be freshly dissected (utilizing the Staples technique) and examined for visceral anomalies and then for skeletal anomalies after ® xation. All rabbit fetuses should be examined for both visceral and skeletal anomalies. The heads of half of the fetuses from each litter should be removed and placed in Bouin's solution and sectioned for identi® cation of brain anomalies. The heads of the remaining half should be sectioned by a single midcoronal incision for evaluation of the internal s tructure of the brain, then processed for evaluation of skeletal alterations . The body of each fetus s hould undergo skeletal analysis.
Because the dam and not the developing organism is the individual treated during ges tation, data generally should be calculated as incidence per litter or as the number and percentage of litters with particular endpoints . In the study report, at leas t the following endpoints s hould be reported: number of corpora lutea and im plants per dam, number of litters w ith r es or ptions , number a nd perce nta ge of feta l deaths per litter, number of live fetuses per litter, sex and weight of each fetus, number of malformed males and females (with type of malformation), number and percentage of fetuses and litters with external, visceral, or s keletal anomalies, summary tables of types and incidences of a nom alies on a litter ba s is , clinical s igns of eff ects on the m other (including type of effect and duration), gross necropsy results, abnormal organs (with histological results ), body weight changes (over ges tation time), feed consumption data, and ¯uid consumption data. Appropriate historical control data may be used in the report to help in the interpretation of the data. Appropriate statis tical techniques s hould be used to compare the values of control and test groups.
In Table 1 , current developmental toxicity guidelines are compared for FDA, EPA, OECD, and ICH. The FDA developmental toxicity study guidelines harmonize well with guidelines from EPA and OECD. Within the ICH guidelines , s om e guidelines differ, and s ome topics are left blank because some guidelines, by de® nition, are left to the investigator. The ICH (U.S. FDA, 1994) guidelines are intended to be more generic, and to allow the persons involved to ªconsider variations in test strategy according to the s tate-of-the-art and ethical s tandards .º
In summary, the following changes have been made in the developmental toxicity guidelines in the FDA's draft of Redbook II: The use of a dose range-® nding study is recommended, preferably in pregnant animals . The number of pregnant rabbits required per group has been increased from 15 to 20. The length of dosing has been extended beyond organogenes is , to accou nt f or effects that can occu r afterw ard. The changes made for the revised developmental toxicity study guidelines respond very favorably to the changes requested in the FDA Survey for Updating Guidelines for the Safety Assessment of Direct Food Additives and Color Additives Used in Food (Collins et al., 1991) .
Reproductive (Multigeneration) Studies Testing Guidelines
The guideline for reproductive s tudies is intended for us e with substances given orally to rodents (primarily rats). It is des igned to evalu- ate the advers e effects of compounds on the reproductive s ystem s of both males and females as well as the postnatal maturation and reproductive capacity of offspring. Also, cumulative effects through several generations may be evaluated. For the FDA, a multigeneration study can provide animals for chronic bioas say studies (in utero expos ure), developmental toxicity s tudies, behavioral studies, and immunotoxicity studies. These studies can also be done as separate s tudies. The minimal reproductive study consis ts of two generations, with one litter per generation. If res ults of developmental or other toxicity tests indicate that a test compound may be associated with developmental toxicity, the minimal reproductive study should be expanded to include, for example, additional litters per generation, additional generations, and a tes t for developmental toxicity.
Because of the length of time and concomitant expense of a multigeneration study, the species s elected for such a study should be one that will yield the greatest amount of information per unit cost. Rats are the preferred species for reproductive toxicity studies. They are small, easily maintained in the laboratory, have a short gestation period, breed eas ily in the laboratory, yield large litters, and are less susceptible to stres s effects than are mice. Test and control animals (5± 9 wk of age) should be acclimated to the s tudy conditions before the s tudy begins. Each test and control group s hould s tart with a number of animals suf-® cient to contain at leas t 20 pregnant females near term. In order to achieve this number, it is usually necessary to start with 30 animals per sex per group in the ® rst parental group (F0) and 25 animals per sex per group (at least 1 male and 1 female from each litter, with a maximum of 2 of each sex per litter) in the parents of each succeeding generation. Mating of animals s hould be done on the bas is of 1 male to 1 female until pregnancy occurs, or 2± 3 wk has elapsed. Mating should be con-® rmed each morning by checking for the presence of sperm in the vaginal lavage or removal of a sperm plug. This is considered day 0 of gestation. The duration of ges tation should be calculated from day 0 of pregnancy. Near par tur ition, pr egnant fem ales s hould be place d in solid-bottom cages with appropriate bedding.
In a reproductive study, the tes t compound is usually administered in the diet or by drinking water, although gavage is a third alternative. The s ame route of administration should be used for all animals in a given study. The males and females should be dosed for 8± 11 wk before mating, throughout the mating period, and until the termination of the animals. In all studies, at a minimum, low, mid, and high doses should be tes ted. The high dose should produce some parental toxicity but not more than 10% parental mortality. This dose should not exceed 5% of the diet for nonnutritive additives. The lowest dose s hould be set at a level that is expected to provide a minimal margin of safety and should not induce any obs ervable adverse parental effects. The intermediate doses s hould be s paced to allow an arithmetic or geometric progress ion between the high and low dos es. A concurrent control group is required. Control animals should be housed in a contaminant-free environment, and fed and handled the same as dosed animals .
Standardization of the number of pups per litter through culling is optional. Litters may be standardized to 8 or 10 pups on the bas is of historical litter size of the strain. It is recommended that standardization be performed on postnatal day 4 by reducing all litters of more than 10 (or 8) to 10 (or 8) in a random manner. If possible, the retained littermates should consist of equal numbers of males and females. Random selection is important to guard against the human tendency to keep the most ® t animals in the study.
Each litter s hould be examined as soon as possible after delivery for the number of pups , stillbirths , live births, and the presence of gross anomalies . Dead pups should be necrops ied and observed for pos sible gross defects and the caus e of death unless excessive autolysis renders specim ens useless . The neonates should be carefully obs erved, sexed, and weighed on postnatal days 0 (day of birth), 4, 7, 14, and 21 (or other appropriate days). Anogenital distance should be measured on day 0 for all F2 pups that show treatment-related effects in F1 sex ratio or sexual maturation. During growth of the pups, relevant behavioral changes and all signs of toxicity, including mortality, should be recorded. Estrous cycle length and normality should be evaluated daily by vaginal smears for all F0 and F1 females during a minimum of 3 wk prior to mating. The age at the time of vaginal opening and preputial separation should be determined for F1 weanlings selected for mating.
At the time of termination or death, all parental animals and two pups per litter from the F1 weanlings not selected for mating and the F2 w ea nlings s hould be exam ined m a cr os copically for any s tr uctura l abnormalities or pathological changes . Special attention should be paid to the organs of the reproduction system. At necropsy, the following organs of all F0 and F1 parental animals s hould be w eighed: uter us , ovaries , tes tes , epididymides (total and cauda), s eminal vesicles (with coagulating glands and their ¯uids) and prostate, brain, liver, kidneys, adrenal glands, spleen, and known target organs . For F1 and F2 weanlings that are examined macroscopically, the brain, spleen, and thymus should be weighed.
The following organs and tis sues, or representative samples thereof, from parental animals should be ® xed and s tored in a s uitable medium for histopathological examination. For the parental (F0 and F1) animals : vagina, uterus w ith ce rvix, ovaries with oviducts , tes tis (pre-served in Bouin's ® xative or comparable preservative), one epididymis, s em ina l ve s icles , pros tat e, coa gu la tin g gla nd, t ar get or ga ns , an d gros sly abnormal tissue. For F1 and F2 weanlings selected for macroscopic examination: gros sly abnormal tis sue and target organs , when known.
Full histopathology of organs from the F0 and F1 parental animals should be performed for all high-dose and control animals selected for mating. Organs demonstrating treatment-related changes should also be examined in the low-and mid-dose groups. Additionally, reproductive organs of the low-and mid-dose animals suspected of reduced fertility, such as those that failed to mate, conceive, sire, or deliver healthy offspring, or for which estrous cyclicity or s perm number, motility, or morphology were affected, should be subjected to histopathological evaluation. B es ides gr os s les ions s uch as atr ophy or tu m ors , tes ticula r histopathological examination should be conducted in order to identify treatment-related effects such as retained s permatids, missing germcell layers or types, multinucleated giant cells, or sloughing of spermatogenic cells into the lumen. The pos tlactational ovary should contain primordial and growing follicles as well as the large corpora lutea of lactation. Histopathological examination should identify depletion of the primordial follicle population. Five ovarian sections should be taken at leas t 0.1 m m (100 µ m ) apart fr om the inner third of each ovary. Examination s hould include enumeration of the total number of primordial follicles from thes e 10 s ections for com paris on with control ovaries. Examination s hould als o confirm the presence or absence of growing follicles and corpora lutea in comparison with control ovaries.
For F1 and F2 weanlings, his topathological characterization of all developmental anomalies noted at macroscopic examination should be performed, with emphasis on the organs of the reproductive system. Data s hould be reported individua lly and s um mar ize d in tabula r form, s howing for each tes t group the types of change and the number of animals dis playing each type of change. An evaluation of test results, including s tatistical analysis, s hould be provided. This should include an evaluation of the relationship, or lack thereof, between the exposure of the animals to the tes t substance and the incidence and s everity of all abnormalities .
Endpoints of reproductive toxicity are usually expressed as indices that encompass the animals' res ponses to the test compound from conception to weaning. The following indices should be calculated for each repr oduction s tudy: f em ale fertility and ges ta tion indice s , w eaning index or lactation index, sex ratio, and viability and growth indices at postnatal days 4, 7, 14, and 21. Endpoints of male reproductive toxicity may als o be assessed if there is evidence of male-mediated effects on developing offspring. The report of the study s hould include at least the following: body weights, feed and ¯uid consumption, clinical observations, female fertility data, pup data by sex (number and weight on days 0, 4, 7, 14, and 21), record of weight of each animal culled (when culling was done), necropsy data, histopathology data of parents and weanlings, estrous cyclicity and time of vaginal opening, time of preputial separation, and organ weights .
Problems commonly encountered in the review of multigeneration studies and developmental toxicity studies include insuf® cient numbers of pregnant animals per control or treatment group, nonrandom selection procedures, and s tatistical analyses of data on a per-fetus basis ins tead of a per-litter bas is . Careful con s ideration of r ecom mended guidelines and the submiss ion of protocols for review by FDA prior to conducting the studies would help eliminate the problems.
Current reproduction guidelines for FDA, EPA, OECD, and ICH are compared in Table 2 . The FDA reproductive study guidelines harmonize w ith EPA and OECD guide lines . In th e ICH guidelin es , a s explained previous ly in the developmental toxicity s ection, some of the guidelines are blank because the ICH guidelines are intended to be generic.
In summary, the following changes have been made to the reproductive study guidelines of the FDA's draft of Redbook II: The number of test generations has been decreased from three to two. The number of litters per generation has been decreased from two to one. Monitoring of the estrous cycle, time of vaginal opening, and time of preputial separation have been added. The amount of histopathology, particularly of the pups, has been increased. The draft Redbook II may undergo further changes before the ® nal version is published. Some of the changes that are being considered include reduced time of male expos ure and limited am ount of pa thological analys is of ovaries , pups , and litter s in the reproduction s tudies.
The changes made for the revis ed r eproduction s tudy guidelines respond very favorably to the changes requested in the FDA Survey for Updating Guidelines for the Safety Assessment of Direct Food Additives and Color Additives Used in Food, reported by Collins et al. (1991) . In addition to the s peci® c changes reported here, ¯exibility and s cienti® c judgment are being encouraged and the use of animals from the reproduction studies for additional s tudies of immunotoxicity, behavior, and developmental toxicity is also encouraged.
The FDA guidelines are keeping pace with the continuing expans ion of the s cience of reproduction and developmental toxicity. The guidelines are also harmonizing with the guidelines being developed for regulatory agencies in this country and around the world. All parental P and F1 animals and all F1 generation (unselected) pups should be examined macros copically for structural abnormalities or pathological changes . Dead or moribund pups s hould be preserved and examined for poss ible defects and/or caus e of death.
Examine each litter to determine implantations , abnormalities , live births , and dead offs pring at birth. Weigh pups at birth. Determine pre-and postweaning s urvival and growth/body weight.
Value of culling is still under discuss ion. U.S . Food and Drug Administration, Center for Food Safety and Applied Nutrition. 1993 . 
